Treatable traits and exacerbation risk in patients with uncontrolled asthma prescribed GINA step 1-3 treatment: A nationwide asthma cohort study.

IF 6.6 2区 医学 Q1 RESPIRATORY SYSTEM Respirology Pub Date : 2024-11-01 Epub Date: 2024-06-10 DOI:10.1111/resp.14774
Jon R Konradsen, Stina Selberg, Maria Ödling, Johanna Karlsson Sundbaum, Apostolos Bossios, Caroline Stridsman
{"title":"Treatable traits and exacerbation risk in patients with uncontrolled asthma prescribed GINA step 1-3 treatment: A nationwide asthma cohort study.","authors":"Jon R Konradsen, Stina Selberg, Maria Ödling, Johanna Karlsson Sundbaum, Apostolos Bossios, Caroline Stridsman","doi":"10.1111/resp.14774","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Uncontrolled asthma in patients treated for mild/moderate disease could be caused by non-pulmonary treatable traits (TTs) that affect asthma control negatively. We aimed to identify demographic characteristics, behavioural (smoking) and extrapulmonary (obesity, comorbidities) TTs and the risk for future exacerbations among patients with uncontrolled asthma prescribed step 1-3 treatment according to the Global Initiative for Asthma (GINA).</p><p><strong>Methods: </strong>Twenty-eight thousand five hundred eighty-four asthma patients (≥18 y) with a registration in the Swedish National Airway Register between 2017 and 2019 were included (index-date). The database was linked to other national registers to obtain information on prescribed drugs 2-years pre-index and exacerbations 1-year post-index. Asthma treatment was classified into step 1-3 or 4-5, and uncontrolled asthma was defined based on symptom control, exacerbations and lung function.</p><p><strong>Results: </strong>GINA step 1-3 included 17,318 patients, of which 9586 (55%) were uncontrolled (UCA 1-3). In adjusted analyses, UCA 1-3 was associated with female sex (OR 1.34, 95% CI 1.27-1.41), older age (1.00, 1.00-1.00), primary education (1.30, 1.20-1.40) and secondary education (1.19, 1.12-1.26), and TTs such as smoking (1.25, 1.15-1.36), obesity (1.23, 1.15-1.32), cardiovascular disease (1.12, 1.06-1.20) and depression/anxiety (1.13, 1.06-1.21). Furthermore, UCA 1-3 was associated with future exacerbations; oral corticosteroids (1.90, 1.74-2.09) and asthma hospitalization (2.55, 2.17-3.00), respectively, also when adjusted for treatment step 4-5.</p><p><strong>Conclusion: </strong>Over 50% of patients treated for mild/moderate asthma had an uncontrolled disease. Assessing and managing of TTs such as smoking, obesity and comorbidities should be conducted in a holistic manner, as these patients have an increased risk for future exacerbations.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"942-950"},"PeriodicalIF":6.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/resp.14774","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Uncontrolled asthma in patients treated for mild/moderate disease could be caused by non-pulmonary treatable traits (TTs) that affect asthma control negatively. We aimed to identify demographic characteristics, behavioural (smoking) and extrapulmonary (obesity, comorbidities) TTs and the risk for future exacerbations among patients with uncontrolled asthma prescribed step 1-3 treatment according to the Global Initiative for Asthma (GINA).

Methods: Twenty-eight thousand five hundred eighty-four asthma patients (≥18 y) with a registration in the Swedish National Airway Register between 2017 and 2019 were included (index-date). The database was linked to other national registers to obtain information on prescribed drugs 2-years pre-index and exacerbations 1-year post-index. Asthma treatment was classified into step 1-3 or 4-5, and uncontrolled asthma was defined based on symptom control, exacerbations and lung function.

Results: GINA step 1-3 included 17,318 patients, of which 9586 (55%) were uncontrolled (UCA 1-3). In adjusted analyses, UCA 1-3 was associated with female sex (OR 1.34, 95% CI 1.27-1.41), older age (1.00, 1.00-1.00), primary education (1.30, 1.20-1.40) and secondary education (1.19, 1.12-1.26), and TTs such as smoking (1.25, 1.15-1.36), obesity (1.23, 1.15-1.32), cardiovascular disease (1.12, 1.06-1.20) and depression/anxiety (1.13, 1.06-1.21). Furthermore, UCA 1-3 was associated with future exacerbations; oral corticosteroids (1.90, 1.74-2.09) and asthma hospitalization (2.55, 2.17-3.00), respectively, also when adjusted for treatment step 4-5.

Conclusion: Over 50% of patients treated for mild/moderate asthma had an uncontrolled disease. Assessing and managing of TTs such as smoking, obesity and comorbidities should be conducted in a holistic manner, as these patients have an increased risk for future exacerbations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
GINA 1-3 级治疗处方中未得到控制的哮喘患者的可治疗特征和病情恶化风险:一项全国性哮喘队列研究。
背景和目的:轻度/中度哮喘患者的哮喘未得到控制可能是由于非肺部可治疗特质(TTs)对哮喘控制产生了负面影响。我们旨在根据全球哮喘防治倡议(GINA),确定未受控制的哮喘患者的人口统计学特征、行为(吸烟)和肺外(肥胖、合并症)TTs,以及未来病情恶化的风险:纳入2017年至2019年期间在瑞典国家气道登记处登记的28 584名哮喘患者(≥18岁)(索引日期)。该数据库与其他国家登记册相连接,以获得指数前两年的处方药信息和指数后一年的病情加重信息。哮喘治疗分为1-3级或4-5级,未控制哮喘的定义基于症状控制、病情加重和肺功能:结果:GINA 第 1-3 步包括 17318 名患者,其中 9586 人(55%)为未控制患者(UCA 1-3)。在调整分析中,UCA 1-3 与女性(OR 1.34,95% CI 1.27-1.41)、年龄较大(1.00,1.00-1.00)、初等教育(1.30,1.20-1.40)和中等教育(1.19,1.12-1.26),以及吸烟(1.25,1.15-1.36)、肥胖(1.23,1.15-1.32)、心血管疾病(1.12,1.06-1.20)和抑郁/焦虑(1.13,1.06-1.21)等 TTs。此外,UCA 1-3 与未来病情恶化、口服皮质类固醇(1.90,1.74-2.09)和哮喘住院治疗(2.55,2.17-3.00)有关,同样在调整治疗步骤 4-5 后也是如此:结论:在接受治疗的轻度/中度哮喘患者中,超过 50%的患者病情未得到控制。对吸烟、肥胖和合并症等 TTs 的评估和管理应全面进行,因为这些患者未来病情恶化的风险会增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Respirology
Respirology 医学-呼吸系统
CiteScore
10.60
自引率
5.80%
发文量
225
审稿时长
1 months
期刊介绍: Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and clinically-relevant experimental respiratory biology and disease. Fields of research include immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology, physiology, paediatric respiratory medicine, clinical trials, interventional pulmonology and thoracic surgery. The Journal aims to encourage the international exchange of results and publishes papers in the following categories: Original Articles, Editorials, Reviews, and Correspondences. Respirology is the preferred journal of the Thoracic Society of Australia and New Zealand, has been adopted as the preferred English journal of the Japanese Respiratory Society and the Taiwan Society of Pulmonary and Critical Care Medicine and is an official journal of the World Association for Bronchology and Interventional Pulmonology.
期刊最新文献
Correction to APSR Annual Conference - 28th Congress of the Asian Pacific Society of Respirology, 7-10 November 2024, Hong Kong. Respirology 29 (Suppl. 3). COPD is associated with increased cardiovascular disease risk independent of phenotype. Letter from Indonesia. Effects of home-based telerehabilitation-assisted inspiratory muscle training in patients with idiopathic pulmonary fibrosis: A randomized controlled trial. Lung cancer (internet-based) Delphi (LUCiD): A modified eDelphi consensus process to establish Australasian clinical quality indicators for thoracic cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1